Page 10 - Julien Vignot News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1

Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaVifor pharmaJulien vignotAngion biomedicaNathalie ponnierStefan schulzeFresenius kabiSwiss stock exchangeGlobal head corporate communicationsSwiss exchangeSwiss federal councilKissei pharmaceutical co ltdDaiichi sankyo groupVifor pharma groupEuropean medicines agency

Vifor Pharma to propose Dr Alexandre LeBeaut as Board member

Press release content from Business Wire. The AP news staff was not involved in its creation. Vifor Pharma to propose Dr Alexandre LeBeaut as Board member February 2, 2021 GMT Regulatory News: Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021. Jacques Theurillat, Chairman of Vifor Pharma, commented: “We are very pleased to nominate Alexandre LeBeaut for election to the Vifor Pharma Group Board of Directors. Dr LeBeaut has broad experience in R&D, clinical development and research/medical affairs. He will optimally complement the Board to assess Vifor Pharma’s pipeline development and clinical programs aiming to become the global leader in iron deficiency, nephrology and cardio-renal therapies.”

France generalAlexandre lebeautVifor pharmaJacques theurillatJulien vignotNathalie ponnierGilbert achermannGianni zampieriVifor pharma group board of directorsSwiss stock exchangeParis universityGlobal head corporate communicationsSwiss exchangeAxcan pharmaceuticalsVifor pharma groupIpsen bioscience inc

VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)

VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
oaoa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from oaoa.com Daily Mail and Mail on Sunday newspapers.

United statesStephanie tomeiVifor pharmaJulien vignotSusanm kanayaDburns mcclellanNathalie ponnierStefan schulzeLee rothThomasj schallSwiss stock exchangeEuropean commissionDrug administrationGlobal head corporate communicationsSwiss exchangeExchange commission

Vifor Fresenius Medical Care Renal Pharma: VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)

(2) As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment The change from baseline to week 26 in C3 glomerulopathy histologic index (C3G HI) for disease activity (primary endpoint) was not statistically different between the two treatment groups, while the C3G HI for disease chronicity (measuring progression of fibrosis) shows significant benefit for avacopan versus placebo Avacopan safe and well tolerated in C3G patients ChemoCentryx and VFMCRP plan to discuss registration pathway with regulatory agencies in US and EU Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005694/en/

United statesStephanie tomeiVifor pharmaJulien vignotSusanm kanayaDburns mcclellanNathalie ponnierStefan schulzeLee rothThomasj schallFresenius medicalSwiss stock exchangeEuropean commissionDrug administrationGlobal head corporate communicationsSwiss exchange